Machine-Learning Research

COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression (TRD.) COMPASS is oner of the biggest players in the psychedelics biotech...

A tech company responsible for creating a clinical testing platform that uses AI and machine learning for the detection of earliest cognitive impairment signs, Cognetivity Neurosciences Ltd. (OTCQB: CGNSF), has completed its non-brokered private placement raising a total $3.323.279. The...

“Language Models Learn Sentiment and Substance from 11,000 Psychoactive Experiences,” is a research project that took nearly 12,000 drug reports with 52 different molecules and combined them with 3 robotics models to characterize all the trajectories of meaning and feeling as...